Steven Z Chao, MD, PHD
Neurology · Palo Alto
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
Offices
1 location
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Chao’s office at (650) 725-6688 to ask if they take your plan before you enroll.
California Medical Board record
Licence A88546 · Current
Licensed to practise in California · since 2004 · expires 2027-11-30 · Rosalind Franklin University, the Chicago Medical School.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Money from drug and device companies
$700 in 2023
| 2023 | 4 | 6 | $150 | $700 |
| 2021 | 1 | 1 | $150 | $150 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Merz North America | Xeomin | $408 | 3 payments
|
| Biogen | Tysabri | $150 | 1 payment
|
| Novo Nordisk | Wegovy | $122 | 1 payment
|
| Chiesi USA | Cleviprex | $20 | 1 payment
|
See all 6 published payments
| Merz North America | Meals · 2023-12-29 | Xeomin | $177 |
| Merz North America | Meals · 2023-09-27 | Xeomin | $200 |
| Chiesi USA | Meals · 2023-07-13 | Cleviprex | $20 |
| Biogen | Consulting · 2023-05-15 | Tysabri | $150 |
| Novo Nordisk | Meals · 2023-02-23 | Wegovy | $122 |
| Merz North America | Meals · 2023-01-27 | Xeomin | $32 |
See earlier years (2021)
2021: $150
| Biogen | Tysabri | $150 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Biogen, Inc. · A Phase 3b/4 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study To Verify the Clinical Benefit of Aducanumab (Biib037) in Participants With Alzheimer'S Disease · 2024 | Their institution | $115,173 |
| Biogen, Inc. · A Phase 3b/4 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study To Verify the Clinical Benefit of Aducanumab (Biib037) in Participants With Alzheimer'S Disease · 2023 | Their institution | $92,014 |
| Biogen, Inc. · A Phase 3b/4 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study To Verify the Clinical Benefit of Aducanumab (Biib037) in Participants With Alzheimer'S Disease · 2025 | Their institution | $5,000 |
Professional record
- NPI
- 1770625667
- Licence
- CA A88546California A88546: Current · expires 2027-11-30
More record details
- Sole proprietor
- Yes
- Taxonomy
- Neurology (2084N0400X)
- Mailing address
- 1120 Welch Rd, 214, Palo Alto, CA, 94304
- NPI first listed
- 2007-02-14
- NPI last updated
- 2007-07-08
This is when the NPI record was last certified, not a medical board exam.